This inventor holds 3 USPTO granted patents and 6 published patent applications. Top assignee: Cornell University. Active years: 2000-2010.
Company Filing History:
Years Active: 2000-2010
Title: Innovations of Neil R Hackett
Introduction
Neil R Hackett is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of genetic engineering and biotechnology. With a total of 3 patents, his work focuses on developing innovative solutions to combat bacterial infections and enhance therapeutic approaches.
Latest Patents
One of his latest patents is titled "Genetic vaccines directed against bacterial exotoxins." This invention provides a gene transfer vector that comprises a humanized nucleic acid sequence encoding an immunogenic portion of one or more exotoxins, along with a heterologous sorting signal. The method outlined in this patent aims to produce an immune response in a host by administering the gene transfer vector.
Another notable patent is "Alternatively spliced nucleic acid molecules." This invention presents an isolated or purified nucleic acid molecule that includes cDNA comprising exons 1-5 of a vascular endothelial growth factor (VEGF) joined to genomic DNA. The invention also describes a mutation in one or more of the splice donor, branch point, and splice acceptor regions, which promotes the production of a VEGF isoform. Expression constructs, compositions, and cells that incorporate such a nucleic acid molecule are also provided.
Career Highlights
Neil R Hackett is affiliated with Cornell University, where he continues to advance research in genetic vaccines and molecular biology. His work has garnered attention for its potential applications in medical science and public health.
Collaborations
He has collaborated with notable colleagues, including Ronald G Crystal and Xiaohuai Zhou, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Neil R Hackett's contributions to the field of biotechnology through his patents and research at Cornell University highlight his commitment to advancing medical science. His innovative approaches to genetic vaccines and molecular biology continue to pave the way for future developments in the industry.